GlassScriptPhysician profile
Coleman T King
NPI 1629171582
$1,632.08
in general payments reported to CMS, 2019-2025
23 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $153 · 2021: $291 · 2022: $369 · 2023: $199 · 2024: $170 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $273.61 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $223.56 | 2021-2025 | |
| Novo Nordisk INC | $158.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $142.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $137.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $100.86 | 2020-2025 | Shingrix, Arexvy |
| Pfizer INC. | $98.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.69 | 2020-2024 | Xifaxan, Trulance |
| Ucb, INC. | $70.14 | 2025 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $59.72 | 2020-2021 | |
| Amgen INC. | $46.58 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.90 | 2022 | |
| Allergan, INC. | $25.36 | 2020 | |
| Bausch Health US, LLC | $24.85 | 2021 | |
| Lundbeck LLC | $22.57 | 2023 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.45 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.13 | 2021 | |
| Gilead Sciences, INC. | $13.60 | 2019 | |
| Sanofi Pasteur INC. | $13.37 | 2020 | |
| Merck Sharp & Dohme LLC | $13.05 | 2023 | Verquvo, Belsomra |
| Teva Pharmaceuticals USA, INC. | $11.79 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coleman King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.